AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus

09.02.2022 AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus | AiCuris Anti-infective Cures AG | News | Nachricht | Mitteilung

Related Keywords

Germany ,Japan ,United States ,Wuppertal ,Nordrhein Westfalen ,Netherlands ,Beest ,Gelderland ,Holger Zimmermann ,Linkedin ,Leiden University Medical Center ,Department Of Nephrology ,Hybridize Therapeutics ,Curis Anti Infective Cures ,Antisense Oligonucleotide ,Finanznachrichten ,D Hoc ,Aktien ,Ktienkurse ,örse ,Apitalmarktinformationen ,Itteilungen ,Achrichten ,News ,Irtschaft ,